Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE 2 14 versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE 2 14 versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
AMMONIUM CHLORIDE 2.14% vs GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood pH and increases renal excretion of alkaline urine.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 mEq) intravenously over 4 to 6 hours; adjust based on serum chloride and pH.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
None Documented
None Documented
4-6 hours; prolonged in renal impairment (up to 12-15 hours).
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Renal: >99% as ammonium ion and chloride; minimal biliary/fecal elimination.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant/Antitussive Combination